Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial - PubMed (original) (raw)
Clinical Trial
. 2011 Dec 15;311(1-2):44-9.
doi: 10.1016/j.jns.2011.04.013. Epub 2011 May 28.
Raymond Hupperts, Frederik Barkhof, Luigi M E Grimaldi, Trygve Holmoy, Joep Killestein, Peter Rieckmann, Myriam Schluep, Reinhold Vieth, Ulrike Hostalek, Lizette Ghazi-Visser, Manolo Beelke; SOLAR study group
Affiliations
- PMID: 21620416
- DOI: 10.1016/j.jns.2011.04.013
Clinical Trial
Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial
Joost Smolders et al. J Neurol Sci. 2011.
Abstract
Recent studies have demonstrated the immunomodulatory properties of vitamin D, and vitamin D deficiency may be a risk factor for the development of MS. The risk of developing MS has, in fact, been associated with rising latitudes, past exposure to sun and serum vitamin D status. Serum 25-hydroxyvitamin D [25(OH)D] levels have also been associated with relapses and disability progression. The identification of risk factors, such as vitamin D deficiency, in MS may provide an opportunity to improve current treatment strategies, through combination therapy with established MS treatments. Accordingly, vitamin D may play a role in MS therapy. Small clinical studies of vitamin D supplementation in patients with MS have reported positive immunomodulatory effects, reduced relapse rates and a reduction in the number of gadolinium-enhancing lesions. However, large randomized clinical trials of vitamin D supplementation in patients with MS are lacking. SOLAR (Supplementation of VigantOL(®) oil versus placebo as Add-on in patients with relapsing-remitting multiple sclerosis receiving Rebif(®) treatment) is a 96-week, three-arm, multicenter, double-blind, randomized, placebo-controlled, Phase II trial (NCT01285401). SOLAR will evaluate the efficacy of vitamin D(3) as add-on therapy to subcutaneous interferon beta-1a in patients with RRMS. Recruitment began in February 2011 and is aimed to take place over 1 calendar year due to the potential influence of seasonal differences in 25(OH)D levels.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
- Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M. Togha M, et al. Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20. Mult Scler. 2010. PMID: 20488825 Clinical Trial. - Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a.
Hupperts R, Smolders J, Vieth R, Holmøy T, Marhardt K, Schluep M, Killestein J, Barkhof F, Beelke M, Grimaldi LME; SOLAR Study Group. Hupperts R, et al. Neurology. 2019 Nov 12;93(20):e1906-e1916. doi: 10.1212/WNL.0000000000008445. Epub 2019 Oct 8. Neurology. 2019. PMID: 31594857 Free PMC article. Clinical Trial. - NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M. Sorensen PS, et al. Lancet Neurol. 2009 Jun;8(6):519-29. doi: 10.1016/S1474-4422(09)70085-7. Epub 2009 May 4. Lancet Neurol. 2009. PMID: 19409854 Clinical Trial. - Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ. Fox EJ. Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review. - PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
Cohen BA, Rivera VM. Cohen BA, et al. Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018. Curr Med Res Opin. 2010. PMID: 20121658 Review.
Cited by
- Vitamin D Supplementation in Functional Recovery of Subjects with Severe Acquired Brain Injury: A Pilot Controlled Randomized Study.
Intiso D, Centra AM, Gravina M, Copetti M, Fontana A, Bartolo M, Filoni S, Di Rienzo F. Intiso D, et al. Neurotrauma Rep. 2024 Jul 1;5(1):606-616. doi: 10.1089/neur.2023.0128. eCollection 2024. Neurotrauma Rep. 2024. PMID: 39036429 - Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.
Freedman MS, Coyle PK, Hellwig K, Singer B, Wynn D, Weinstock-Guttman B, Markovic-Plese S, Galazka A, Dangond F, Korich J, Reder AT. Freedman MS, et al. Neurol Ther. 2024 Apr;13(2):283-322. doi: 10.1007/s40120-023-00565-7. Epub 2024 Jan 11. Neurol Ther. 2024. PMID: 38206453 Free PMC article. Review. - Changes in the Expression of TGF-Beta Regulatory Pathway Genes Induced by Vitamin D in Patients with Relapsing-Remitting Multiple Sclerosis.
Lozano-Ros A, Martínez-Ginés ML, García-Domínguez JM, Salvador-Martín S, Goicochea-Briceño H, Cuello JP, Meldaña-Rivera A, Higueras-Hernández Y, Sanjurjo-Sáez M, Álvarez-Sala-Walther LA, López-Fernández LA. Lozano-Ros A, et al. Int J Mol Sci. 2023 Sep 22;24(19):14447. doi: 10.3390/ijms241914447. Int J Mol Sci. 2023. PMID: 37833895 Free PMC article. - Clinical and Imaging Outcomes after Vitamin D Supplementation in Patients with Multiple Sclerosis: A Systematic Review.
Langlois J, Denimal D. Langlois J, et al. Nutrients. 2023 Apr 18;15(8):1945. doi: 10.3390/nu15081945. Nutrients. 2023. PMID: 37111166 Free PMC article. Review. - Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis.
Mimpen M, Rolf L, Poelmans G, van den Ouweland J, Hupperts R, Damoiseaux J, Smolders J. Mimpen M, et al. PLoS One. 2021 Dec 2;16(12):e0261097. doi: 10.1371/journal.pone.0261097. eCollection 2021. PLoS One. 2021. PMID: 34855907 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous